Residency · Residency · Pediatrics

Pediatric Obstructive Sleep Apnea

Overview

Obstructive sleep apnea (OSA) affects 1-5% of children, with peak prevalence between ages 2 and 8 years when adenotonsillar hypertrophy is most prominent. A second peak occurs in adolescence, driven primarily by obesity. The condition is characterized by recurrent episodes of partial or complete upper airway obstruction during sleep. Pediatric OSA is distinct from adult OSA in its pathophysiology, clinical presentation, polysomnographic criteria, and treatment approach. Left untreated, OSA carries significant neurocognitive, behavioral, cardiovascular, and growth consequences.

Pathophysiology

Adenotonsillar hypertrophy is the most common cause of OSA in otherwise healthy children. During sleep, decreased muscle tone exacerbates upper airway narrowing caused by enlarged tonsils and adenoids. Several additional factors can contribute, including craniofacial abnormalities (micrognathia, midface hypoplasia), obesity, neuromuscular disorders, Down syndrome, and mucopolysaccharidoses. The downstream consequences of OSA are driven by intermittent hypoxemia and sleep fragmentation. In obesity-related OSA specifically, fat deposition in pharyngeal tissues combines with reduced lung volumes and increased airway collapsibility to worsen obstruction.

Clinical Presentation

Nighttime Symptoms

Habitual snoring is present in roughly 10% of children, though only 1-5% have true OSA. Caregivers may witness frank apneas or gasping episodes. The child often has restless sleep with frequent position changes, diaphoresis during sleep, and paradoxical chest and abdominal movement. Secondary enuresis can also develop.

Daytime Symptoms

Unlike adults, excessive daytime sleepiness is less common in children with OSA. Instead, the hallmark daytime manifestations are behavioral: hyperactivity, inattention, and aggression that may closely mimic ADHD. Morning headaches, poor school performance, mouth breathing, and nasal voice are also common. In severe cases, failure to thrive can occur from increased caloric expenditure during disrupted sleep.

Physical Examination Findings

Key findings include tonsillar hypertrophy (graded on the Brodsky scale from 0 to 4+), adenoid facies (elongated face, open mouth posture, high-arched palate), obesity (BMI at or above the 95th percentile), micrognathia or retrognathia, and nasal obstruction with turbinate hypertrophy.

<image>Clinical features of pediatric obstructive sleep apnea showing adenotonsillar hypertrophy (Brodsky grade comparison), adenoid facies with open mouth posture and high-arched palate, and polysomnographic tracing demonstrating obstructive apnea with paradoxical respiratory effort and oxygen desaturation</image>

Diagnosis

Polysomnography (PSG)

Polysomnography is the gold standard for diagnosing OSA in children. It is performed as an attended overnight study in a sleep laboratory. Pediatric scoring criteria differ significantly from adult criteria. An obstructive apnea in a child is defined as cessation of airflow for two or more missed breaths (rather than the 10-second threshold used in adults), and a hypopnea requires at least a 30% reduction in airflow with either a 3% or greater desaturation or an arousal. | AHI (events/hour) | Severity | Management |

The Apnea-Hypopnea Index (AHI) is interpreted more stringently in children: an AHI below 1 event per hour is normal, 1-5 per hour indicates mild OSA, 5-10 per hour indicates moderate OSA, and greater than 10 per hour indicates severe OSA. Additional data from the study includes nadir SpO2, CO2 levels, sleep architecture, and the arousal index.

When to Order PSG

The AAP recommends polysomnography before adenotonsillectomy to document disease severity, though practice varies. PSG is mandatory in several high-risk groups: obese children, those with Down syndrome, craniofacial anomalies, neuromuscular disease, or when there is a discrepancy between the reported symptoms and the physical examination. Screening questionnaires such as the Pediatric Sleep Questionnaire (PSQ) and Sleep-Related Breathing Disorder (SRBD) scale have limited sensitivity and specificity and cannot replace polysomnography.

Home Sleep Apnea Testing (HSAT)

Home sleep apnea testing is not validated or recommended in children. It lacks the EEG monitoring, CO2 measurement, and attended observation necessary for proper pediatric interpretation.

Management

Adenotonsillectomy (AT)

Adenotonsillectomy is the first-line treatment for OSA in children with adenotonsillar hypertrophy, with a cure rate of approximately 75-80% in non-obese children but only 25-50% in obese children. The landmark CHAT trial (Childhood Adenotonsillectomy Trial) demonstrated that AT improved behavior, quality of life, and polysomnographic parameters compared to watchful waiting at 7 months, although notably 46% of the watchful waiting group experienced spontaneous resolution. Post-operative polysomnography is recommended for obese children, those with severe OSA, persistent symptoms, Down syndrome, or craniofacial anomalies. Children with severe OSA are at risk for postoperative respiratory compromise and should be considered for overnight monitoring after surgery.

Positive Airway Pressure (PAP)

CPAP is the second-line therapy for residual OSA after adenotonsillectomy or when surgery is contraindicated. Pediatric-specific masks and pressure settings are required. Adherence is the major challenge, and behavioral support programs with desensitization techniques can help. Auto-titrating PAP (APAP) may improve tolerance in some children.

Weight Management

Weight management is essential in obese children with OSA. Even modest weight loss of 5-10% reduction in BMI can significantly reduce the AHI. In obese adolescents with mild OSA, weight loss alone may be sufficient as the primary treatment.

Other Interventions

Intranasal corticosteroids such as fluticasone or mometasone may reduce the AHI by approximately 25% in mild OSA and are useful as adjuncts after adenotonsillectomy for residual symptoms. Montelukast has some evidence supporting its use for mild residual OSA through anti-inflammatory effects on lymphoid tissue. Orthodontic and dental interventions include rapid maxillary expansion for children with a high-arched palate and mandibular advancement devices in adolescents. Hypoglossal nerve stimulation is FDA-approved for Down syndrome patients aged 13 years and older with OSA refractory to other therapies. Myofunctional therapy, which involves oropharyngeal exercises to improve muscle tone, has emerging evidence supporting its use.

<image>Treatment algorithm for pediatric OSA showing initial assessment, first-line adenotonsillectomy for adenotonsillar hypertrophy, post-AT PSG for high-risk groups, and second-line options including CPAP, weight management, intranasal steroids, orthodontic interventions, and hypoglossal nerve stimulation for specific populations</image>

Consequences of Untreated OSA

Neurocognitive and Behavioral

Untreated OSA leads to inattention, hyperactivity, and impulsivity with significant overlap with ADHD symptoms. Children may show decreased IQ scores and executive function deficits, poor academic performance, and mood dysregulation with anxiety.

Cardiovascular

Cardiovascular consequences include systemic hypertension, right ventricular hypertrophy progressing to cor pulmonale in severe cases, endothelial dysfunction, and elevated inflammatory markers such as CRP and IL-6.

Growth and Metabolic

OSA can cause failure to thrive through increased energy expenditure and disrupted growth hormone secretion. It is also associated with insulin resistance and metabolic syndrome, particularly in obese children. Paradoxically, both failure to thrive and obesity can be associated with pediatric OSA.

Special Populations

Down Syndrome

The prevalence of OSA in children with Down syndrome is remarkably high at 50-80%, driven by midface hypoplasia, glossoptosis, hypotonia, and obesity. The AAP recommends polysomnography by age 4 years in all children with Down syndrome. Adenotonsillectomy is less effective in this population, with only about a 50% cure rate, and many children require CPAP or additional interventions. Hypoglossal nerve stimulation is an emerging option for these patients.

Craniofacial Anomalies

Children with Pierre Robin sequence, Treacher Collins syndrome, or Apert syndrome may require mandibular distraction, tracheostomy, or other surgical interventions for airway management. Multidisciplinary management is essential.

<image>Comparison of OSA characteristics in different pediatric populations: otherwise healthy children (adenotonsillar hypertrophy as primary cause, high AT cure rate), obese children (multifactorial, lower AT cure rate, weight loss important), and Down syndrome (midface hypoplasia, hypotonia, low AT cure rate, often needs multimodal therapy)</image>

Clinical Pearls

Pediatric OSA criteria are fundamentally different from adults: an AHI of 2 per hour is abnormal in a child but normal in an adult. While snoring alone is common and usually benign, the key is identifying associated symptoms such as witnessed apneas, behavioral changes, and enuresis. Children with ADHD symptoms refractory to treatment should be screened for OSA, since sleep disruption can mimic or exacerbate ADHD. Obese children have a much lower adenotonsillectomy cure rate (approximately 25-50%), so clinicians should set realistic expectations and plan for post-operative polysomnography. Every child with Down syndrome should have a sleep study by age 4, regardless of symptoms. After adenotonsillectomy, many families assume the problem is resolved, but residual OSA is common and follow-up polysomnography should be considered in high-risk patients.

Key Controversy: Drug-Induced Sleep Endoscopy (DISE) for Persistent OSA

Drug-induced sleep endoscopy involves flexible laryngoscopy under propofol sedation to identify the anatomic level or levels of obstruction. Proponents argue it guides targeted surgical intervention in children with persistent OSA after adenotonsillectomy. The technique can identify lingual tonsil hypertrophy, laryngomalacia, glossoptosis, and pharyngeal collapse not evident on awake examination. Concerns remain that propofol sedation may not replicate natural sleep physiology, and variable protocols and scoring systems limit standardization. The role of orthodontic interventions such as rapid maxillary expansion and mandibular advancement guided by DISE findings is evolving. Currently, DISE is used selectively at specialized centers, and no consensus guidelines exist regarding its indications or timing.

References

• Marcus CL, et al. Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome (AAP Clinical Practice Guideline). Pediatrics. 2012;130(3):e714-e755.
• Marcus CL, et al. A Randomized Trial of Adenotonsillectomy for Childhood Sleep Apnea (CHAT Trial). N Engl J Med. 2013;368(25):2366-2376.
• Bitners AC, Arens R. Evaluation and Management of Children with Obstructive Sleep Apnea Syndrome. Lung. 2020;198(2):257-270.
• Farhood Z, et al. Drug-Induced Sleep Endoscopy in the Pediatric Population: A Systematic Review. Otolaryngol Head Neck Surg. 2017;156(2):239-249.
• Cielo CM, et al. Obstructive Sleep Apnea in Children with Down Syndrome. Paediatr Respir Rev. 2022;44:38-44.

Read this lecture as Markdown